Advertisement

The Latest

A study reveals that the pain medication Vioxx suppressed the production of enzymes that play a key role protecting the heart, according to a Wall Street Journal report.

Drug developer Zalicus is advancing its neuropathic pain drug candidate, Z160, into multiple Phase 2 clinical trials, according to a Mass High Tech report. Z160 is an oral, N-type calcium channel blocker for neuropathic pain.

Advertisement